Making Ibrutinib + Venetoclax available as a first line treatment in Canada

[CLL_Canada_Group]

If you have CLL and have been treated with a combination of Ibrutinib + Venetoclax as your first treatment, you can help by completing our survey. The results will be used in a submission to two Canadian governmental agencies assessing Ibrutinib and Venetoclax as a first-line treatment.

Please use the link below to complete the survey, regardless of where you live.

Our goal is to ensure that the views of patients are reflected in the recommendations made by these two agencies to Provincial and Territorial Health Ministers regarding the funding of the combination of Ibrutinib and Venetoclax as a first line treatment to CLL patients.

Please complete this survey if you have been treated with Ibrutinib + Venetoclax as your first treatment.

You do not need to live in Canada to complete this survey.

Click here to participate in the survey: surveymonkey.com/r/2H8V79D

The survey and the submission are a joint initiative of Lymphoma Canada and CLL Canada. The two agencies reviewing Ibrutinib and Venetoclax as a first line treatment are Canadian Agency for Drugs and Technologies in Health (cadth.ca) and the Institut national d'excellence en santé et en services sociaux in Quebec (inesss.qc.ca)

[PoisonDwarf]

As UK NICE have now approved Ibrutinib & Venetoclax as a first line treatment for all patients it would be nice to think that Canada will follow suit sooner than later. I hope that decision & the evidence used will add weight to any canadian submission.